Tab Article
"Diagnosis, risk stratification, selection of therapy, interim/post-therapy evaluation by MRD/PET-CT-based investigations, and subsequent modification of the therapeutic procedure have transformed the overall outcome of hematological malignancies. Molecular investigations are a requirement at all stages: Diagnosis, risk stratification, interim/MRD evaluation, etc. Matched unrelated donor/Haplo Allo BMT has enhanced the possibility of Allo BMT in most of the patients as a curative option. This first joint venture ICH-ICP e-Monogram, highlighting the above points, is primarily meant for postgraduates."













Guest User
Verified PurchaseThe mobile app is very easy to navigate and there are daily notifications of new arrivals and discounts.?